Pfizer's C. difficile Vaccine Succeeds in Phase II Study
February 2nd 2017Researchers found the experimental vaccine could potentially inhibit severe diarrhea and pseudomembranous colitis by inducing a functional antibody response that can neutralize the two main disease-causing toxins (toxin A or B) produced by C. difficile.
Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases
February 1st 2017In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.
Treatment Options for HCV Patients with Renal Impairment
February 1st 2017A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.